ECSP19030134A - Compuesto de piridina - Google Patents

Compuesto de piridina

Info

Publication number
ECSP19030134A
ECSP19030134A ECSENADI201930134A ECDI201930134A ECSP19030134A EC SP19030134 A ECSP19030134 A EC SP19030134A EC SENADI201930134 A ECSENADI201930134 A EC SENADI201930134A EC DI201930134 A ECDI201930134 A EC DI201930134A EC SP19030134 A ECSP19030134 A EC SP19030134A
Authority
EC
Ecuador
Prior art keywords
pyridine compound
pharmaceutically acceptable
acceptable salt
compound
formula
Prior art date
Application number
ECSENADI201930134A
Other languages
English (en)
Inventor
Yasuyuki Kaneta
Yoshihiro Shibata
Hiroaki Inagaki
Hidenori Namiki
Kiyoshi Nakayama
Hideaki Kageji
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of ECSP19030134A publication Critical patent/ECSP19030134A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención tiene relación con un compuesto que tiene acción inhibidora de quinasa RET o una sal farmacéuticamente aceptable del mismo, útil en el tratamiento de enfermedades como cáncer. En particular un compuesto representado por la siguiente fórmula general (I) como se define en este documento: [Fórmula I] (ver figura) o una sal farmacéuticamente aceptable del mismo.
ECSENADI201930134A 2016-09-29 2019-04-29 Compuesto de piridina ECSP19030134A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016191725A JP2018052878A (ja) 2016-09-29 2016-09-29 ピリジン化合物
PCT/GB2017/052913 WO2018060714A1 (en) 2016-09-29 2017-09-28 Pyridine compound

Publications (1)

Publication Number Publication Date
ECSP19030134A true ECSP19030134A (es) 2019-08-30

Family

ID=60020249

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201930134A ECSP19030134A (es) 2016-09-29 2019-04-29 Compuesto de piridina

Country Status (32)

Country Link
US (2) US10851092B2 (es)
EP (2) EP3828178A1 (es)
JP (2) JP2018052878A (es)
KR (1) KR102520543B1 (es)
CN (2) CN113788824A (es)
AU (2) AU2017335242C1 (es)
BR (1) BR112019006047A2 (es)
CA (1) CA3035860A1 (es)
CL (1) CL2019000844A1 (es)
CO (1) CO2019004034A2 (es)
CY (1) CY1123988T1 (es)
DK (1) DK3519398T3 (es)
EA (1) EA037103B1 (es)
EC (1) ECSP19030134A (es)
ES (1) ES2868748T3 (es)
HR (1) HRP20210447T1 (es)
HU (1) HUE054824T2 (es)
IL (1) IL265630B (es)
LT (1) LT3519398T (es)
MA (2) MA46337B1 (es)
MD (1) MD3519398T2 (es)
MX (1) MX2019003747A (es)
PE (1) PE20190805A1 (es)
PH (1) PH12019500480A1 (es)
PL (1) PL3519398T3 (es)
PT (1) PT3519398T (es)
RS (1) RS61640B1 (es)
SG (1) SG11201901937WA (es)
SI (1) SI3519398T1 (es)
UA (1) UA123964C2 (es)
WO (1) WO2018060714A1 (es)
ZA (1) ZA201902232B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3371171T3 (fi) 2015-11-02 2024-01-10 Blueprint Medicines Corp Ret:n estäjiä
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
US20210100795A1 (en) 2018-04-03 2021-04-08 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021100677A1 (ja) * 2019-11-18 2021-05-27 中外製薬株式会社 併用医薬
CN113121524B (zh) 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115210226B (zh) * 2020-02-20 2024-01-09 广州白云山医药集团股份有限公司白云山制药总厂 喹啉类化合物
WO2021164741A1 (zh) * 2020-02-20 2021-08-26 南京明德新药研发有限公司 苯基双酰胺类化合物
WO2022238706A1 (en) 2021-05-14 2022-11-17 Bp Asset Viii, Inc. Ret inhibitor for the treatment of ret altered medullary thyroid cancer or ret altered non-small cell lung cancer
WO2023239422A2 (en) 2021-10-22 2023-12-14 University Of Houston System Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues
CN115090331B (zh) * 2022-07-21 2023-05-16 扬州大学 超分子手性催化剂、其制备方法及其催化d-a反应的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
AU2004270733B2 (en) 2003-09-11 2011-05-19 Itherx Pharma, Inc. Cytokine inhibitors
EP1994023A1 (en) 2006-03-02 2008-11-26 AstraZeneca AB Quinazoline derivatives
JP2009528336A (ja) 2006-03-02 2009-08-06 アストラゼネカ アクチボラグ キノリン誘導体
WO2007113548A1 (en) 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives
WO2007113565A1 (en) 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives as anti-cancer agents
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
ES2459722T3 (es) * 2009-02-27 2014-05-12 Teijin Pharma Limited Procedimiento para producir un derivado heterocíclico sustituido con fenilo mediante acoplamiento usando un catalizador de metal de transición
EP2467137A1 (en) 2009-08-19 2012-06-27 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
RU2561055C2 (ru) 2009-08-25 2015-08-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Комбинированная терапия композициями наночастиц таксана и ингибиторами хэджхог
WO2011133728A2 (en) 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
US9073895B2 (en) 2010-12-16 2015-07-07 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
CA2878895A1 (en) 2012-07-13 2014-01-16 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
AU2014229233B2 (en) * 2013-03-15 2016-08-11 Glaxosmithkline Intellectual Property Development Limited Pyridine derivatives as rearranged during transfection (RET) kinase inhibitors
RU2016111675A (ru) * 2013-08-30 2017-10-04 Эмбит Байосайенсиз Корпорейшн Соединения биарилацетамида и способы их применения
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
EP3135667A4 (en) * 2014-04-24 2017-11-01 Mitsubishi Tanabe Pharma Corporation Novel 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof
CR20170094A (es) * 2014-09-10 2017-05-08 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret)
SG11201701694QA (en) * 2014-09-10 2017-04-27 Glaxosmithkline Ip Dev Ltd Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
CN107427506A (zh) 2014-10-14 2017-12-01 拉霍拉敏感及免疫学研究所 低分子量蛋白酪氨酸磷酸酶的抑制剂及其用途
CN104844589B (zh) 2014-12-26 2018-04-20 中国科学院合肥物质科学研究院 一种pi3k激酶抑制剂
US10202365B2 (en) * 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
AU2016291676B2 (en) 2015-07-16 2020-04-30 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物

Also Published As

Publication number Publication date
JP2019534871A (ja) 2019-12-05
CN113788824A (zh) 2021-12-14
IL265630A (en) 2019-05-30
RS61640B1 (sr) 2021-04-29
IL265630B (en) 2021-10-31
MA54910A (fr) 2022-04-13
CL2019000844A1 (es) 2019-06-07
PL3519398T3 (pl) 2021-06-28
LT3519398T (lt) 2021-05-10
EA037103B1 (ru) 2021-02-05
UA123964C2 (uk) 2021-06-30
EA201990833A1 (ru) 2019-10-31
SG11201901937WA (en) 2019-04-29
AU2017335242B2 (en) 2021-08-19
EP3519398A1 (en) 2019-08-07
HRP20210447T1 (hr) 2021-07-23
MD3519398T2 (ro) 2021-05-31
AU2021261899A1 (en) 2021-12-02
JP7098609B2 (ja) 2022-07-11
KR20190086442A (ko) 2019-07-22
HUE054824T2 (hu) 2021-10-28
CA3035860A1 (en) 2018-04-05
US20210163464A1 (en) 2021-06-03
AU2017335242C1 (en) 2021-12-09
PT3519398T (pt) 2021-03-24
ES2868748T3 (es) 2021-10-21
WO2018060714A1 (en) 2018-04-05
SI3519398T1 (sl) 2021-07-30
CY1123988T1 (el) 2022-05-27
EP3828178A1 (en) 2021-06-02
US10851092B2 (en) 2020-12-01
EP3519398B1 (en) 2021-02-24
BR112019006047A2 (pt) 2019-06-25
CO2019004034A2 (es) 2019-07-10
AU2017335242A1 (en) 2019-05-02
MX2019003747A (es) 2019-09-19
US20200039974A1 (en) 2020-02-06
DK3519398T3 (da) 2021-03-29
MA46337A (fr) 2019-08-07
ZA201902232B (en) 2022-12-21
CN110036007A (zh) 2019-07-19
PH12019500480A1 (en) 2019-08-05
MA46337B1 (fr) 2021-04-30
CN110036007B (zh) 2021-10-15
JP2018052878A (ja) 2018-04-05
PE20190805A1 (es) 2019-06-10
KR102520543B1 (ko) 2023-04-10

Similar Documents

Publication Publication Date Title
ECSP19030134A (es) Compuesto de piridina
ECSP18093777A (es) Derivados de pirazolopirimidina como inhibidor de quinasa
ECSP20035222A (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa
CO2020007156A2 (es) Derivado de amino-metil piperidina como inhibidor de quinasa
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
DOP2020000112A (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
PE20151654A1 (es) Inhibidores de cdc7
CO2017012067A2 (es) Derivado de pirido[3,4–d]pirimidina y sal farmacéuticamente aceptable de éste
CO2017004784A2 (es) Isómeros de ácido-1-[(3-cloro-2-fluoro-fenil)metil]-4-[[3-fluoro-6-[(5-metil-1h-pirazol-3-il)amino]-2-piridil]metil]-2-metil-piperidin-4-carboxílico como inhibidores de la cinasa aurora a
CU20160195A7 (es) Derivados de quinolizinona como inhibidores de pi3k
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
GT201600232A (es) Derivados de diheterociclo enlazado a cicloalquilo
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
AR115865A2 (es) Compuestos terapéuticos
UY35317A (es) Compuesto de ciclopropanoamina